Hepatitis B: Chronic Infection, Antivirals, and Vaccination

Imagine carrying a virus that silently attacks your liver for decades without you ever knowing it. That is the reality for millions of people living with chronic hepatitis B. Unlike the flu or a common cold, this infection doesn't always announce itself with fever or fatigue. Instead, it can sit quietly in your body, slowly damaging liver tissue until serious complications like cirrhosis or liver cancer develop. But here is the good news: we have powerful tools to stop it. Modern antiviral medications can suppress the virus so effectively that many people live long, healthy lives, and a vaccine exists to prevent new infections entirely.

Understanding Chronic Hepatitis B Infection

To manage chronic hepatitis B, you first need to understand what makes it different from other liver viruses. The hepatitis B virus (HBV) was identified in the 1960s by Dr. Baruch Blumberg, a discovery that eventually earned him a Nobel Prize. Today, we know that HBV infects liver cells and uses them to replicate. If your immune system cannot clear the virus within six months, the infection becomes chronic. This means the hepatitis B surface antigen (HBsAg) remains in your blood for at least half a year.

The global burden is significant. According to the World Health Organization (WHO), approximately 296 million people were living with chronic HBV in 2019, leading to around 820,000 deaths annually, mostly due to cirrhosis and hepatocellular carcinoma. In the United States, the CDC estimates that about 862,000 people have chronic HBV, though this number is likely higher because many cases go undiagnosed. The key challenge is that early-stage chronic hepatitis B often has no symptoms. You might feel perfectly fine while the virus is causing low-grade inflammation and fibrosis (scarring) in your liver.

When Should You Start Treatment?

Not everyone with chronic hepatitis B needs medication immediately. Doctors look at three main factors to decide if treatment is necessary:

• Fibrosis status: How much scarring is present in the liver? This is assessed through non-invasive tests like FibroScan or, less commonly, a biopsy.
• ALT levels: Alanine aminotransferase is an enzyme released when liver cells are damaged. High ALT indicates active inflammation.
• HBV DNA levels: This measures how much virus is replicating in your blood.

Guidelines have shifted significantly in recent years. The 2024 WHO HBV guidelines now recommend treating all adults with HBV DNA levels of 2,000 IU/mL or higher, regardless of their ALT levels or fibrosis stage. This is a major change from older protocols that waited for signs of liver damage before starting drugs. The goal is to intervene earlier to prevent progression to cirrhosis. For patients who already have compensated cirrhosis, treatment is recommended for everyone, no matter their viral load or ALT levels. If you have decompensated cirrhosis (where the liver is failing), you should start oral antivirals immediately and be evaluated for a liver transplant.

First-Line Antiviral Medications

If you need treatment, there are two main categories of drugs: nucleos(t)ide analogs (oral pills) and pegylated interferon (injections). Oral medications are generally preferred because they are easier to take and have fewer side effects. The current gold standards include:

1. Tenofovir Disoproxil Fumarate (TDF): A potent antiviral that has been used for years. It is highly effective at suppressing the virus but can sometimes affect kidney function and bone density over time.
2. Entecavir (ETV): Another strong option with a high barrier to resistance, meaning the virus rarely mutates to escape its effects.
3. Tenofovir Alafenamide (TAF): Marketed as Vemlidy, this is the newer version of TDF. It delivers the drug more efficiently to liver cells, allowing for a lower dose. Clinical trials show it provides comparable efficacy to TDF but with better safety for kidneys and bones. It is now considered a preferred first-line therapy in major guidelines, including those from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL).

Dr. Anna S. Lok, a leading expert in hepatitis B, notes that TAF offers a crucial option for patients who have existing renal or bone concerns. If you are switching from TDF to TAF, you may see improvements in proteinuria and bone mineral density within the first 24 weeks.

Vaccination: Prevention Is Key

While antivirals manage existing infection, the hepatitis B vaccine prevents it. This vaccine is one of the most successful public health tools ever developed. It works by stimulating your immune system to produce antibodies against the hepatitis B surface antigen without exposing you to the actual virus. The standard series involves three shots given over six months, though accelerated schedules exist for travelers or post-exposure situations.

Who needs the vaccine? Ideally, everyone should be vaccinated. The CDC recommends universal infant vaccination, which has dramatically reduced new infections in children. However, many adults born before widespread vaccination programs remain unvaccinated. If you are unvaccinated and have risk factors-such as having multiple sexual partners, sharing needles, or working in healthcare-you should get tested for immunity (anti-HBs) and vaccinated if negative. Post-exposure prophylaxis (PEP) is also critical. If you are exposed to blood or body fluids from someone with unknown HBV status, receiving both the vaccine and Hepatitis B Immune Globulin (HBIG) within 24 hours is highly effective at preventing infection.

Special Populations and Co-Infections

Hepatitis B rarely travels alone. Managing co-infections requires careful planning. The 2025 guidelines emphasize specific strategies for these groups:

• HIV/HBV Co-infection: All patients with both HIV and HBV should start HIV treatment immediately using regimens that include HBV-active antivirals (like TDF or TAF). Stopping HBV meds can cause a dangerous flare-up of hepatitis.
• HCV/HBV Co-infection: If you are being treated for Hepatitis C with direct-acting antivirals (DAAs), you must concurrently receive oral anti-HBV therapy. DAAs can reactivate HBV if not covered by an antiviral.
• Pregnancy: To prevent mother-to-child transmission, pregnant women with high viral loads (HBV DNA ≥5.3 log10 IU/mL) should start tenofovir at week 28 of pregnancy. Newborns also receive the vaccine and HBIG within 12 hours of birth.
• Hepatitis D (HDV): HDV only infects people who already have HBV. Experts now recommend reflex testing for HDV in all HBsAg-positive individuals because HDV accelerates liver damage significantly.

Monitoring and Long-Term Care

Starting medication is just the beginning. Chronic hepatitis B management is a marathon, not a sprint. You will need regular monitoring to ensure the virus stays suppressed and to watch for side effects. Typical follow-up includes:

• Every 3-6 months: Blood tests for ALT, HBV DNA, and renal function (if on TDF/TAF).
• Every 6 months: Ultrasound or AFP blood test to screen for hepatocellular carcinoma (liver cancer), especially if you have cirrhosis or are over age 40.
• Quantitative HBsAg: Some experts use this test to help predict who might achieve a "functional cure" (loss of HBsAg) if treatment is stopped, though this is still an area of active research.

Adherence is critical. Missing doses can lead to viral rebound and drug resistance. Studies show that in low- and middle-income countries, only 10-20% of eligible people receive appropriate therapy, highlighting a major gap in global care. In high-income settings, adherence is better but still requires patient education and support.

Future Directions: The Quest for a Cure

Current antivirals suppress the virus but rarely eliminate it completely because HBV hides in the liver as covalently closed circular DNA (cccDNA). Scientists are working hard to change this. As of 2024, at least 15 novel compounds are in clinical development targeting cccDNA, viral entry, and immune modulation. These combination therapies aim to achieve a functional cure, defined as the loss of HBsAg with or without antibody seroconversion.

Dr. Steven-Huy Han of UCLA predicts that by 2030, we may have functional cures for 30-40% of patients through these multi-target approaches. While we wait for these breakthroughs, sticking to current guidelines, taking your prescribed antivirals, and getting vaccinated (or ensuring your family is) remains the best defense against this silent killer.